Identification of MCAM/CD146 as the Target Antigen of a Human Monoclonal Antibody that Recognizes Both Epithelioid and Sarcomatoid Types of Mesothelioma

Scott Bidlingmaier,1 Jiang He,2 Yong Wang,1 Feng An,1 Jinjin Feng,2 Dario Barbone,3 Dongwei Gao,2 Ben Franc,1 V. Courtney Broaddus,1,4 and Bin Liu1

1Department of Anesthesia, 2Center for Functional and Molecular Imaging, Department of Radiology, 3Lung Biology Center, Department of Medicine, San Francisco General Hospital; 4Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California

Abstract

The prognosis for patients diagnosed with mesothelioma is generally poor, and currently available treatments are usually ineffective. Therapies that specifically target tumor cells hold much promise for the treatment of cancers that are resistant to current approaches. We have previously selected phage antibody display libraries on mesothelioma cell lines to identify a panel of internalizing human single chain (scFv) antibodies that target mesothelioma-associated, clinically represented cell surface antigens and further exploited the internalizing function of these scFvs to specifically deliver lethal doses of liposome-encapsulated small molecule drugs to both epithelioid and sarcomatous subtypes of mesothelioma cells. Here, we report the identification of MCAM/MUC18/CD146 as the surface antigen bound by one of the mesothelioma-targeting scFvs using a novel cloning strategy based on yeast surface human proteome display. Immunohistochemical analysis of mesothelioma tissue microarrays confirmed that MCAM is widely expressed by both epithelioid and sarcomatous subtypes of mesothelioma cells. Thus, the development of targeted cancer therapies against mesothelioma will benefit from the identification of additional cell surface markers with more restricted expression by normal mesothelial cells (16). Thus, the development of targeted cancer therapies will benefit from the identification of additional cell surface markers with more restricted expression by normal mesothelial cells (16).

Introduction

Mesothelioma is a deadly disease caused by malignant transformation of the mesothelium, the protective lining surrounding most of the internal organs of the body. Mesothelioma is almost always associated with previous exposure to asbestos, and symptoms may not appear until 20 to 50 years after exposure (1). There is no generally accepted method for screening patients who have been exposed to asbestos, and diagnosis can be difficult because the symptoms of mesothelioma are similar to those caused by other conditions (2). There are three main types of mesothelioma: epithelioid, sarcomatoid, and mixed (3, 4). Epithelioid mesothelioma is the most common form, comprising between 50% and 70% of mesothelioma cases, and is the most likely to respond to treatment (4). Sarcomatoid mesothelioma accounts for 10% to 20% of mesothelioma cases and rarely responds to treatment (4, 5). Approximately 20% to 35% of mesothelioma cases are mixed type, which contains both epithelioid and sarcomatoid features and has an intermediate outlook (4, 6). Regardless of subtype, because diagnosis often occurs at a late stage of disease, the prognosis for malignant mesothelioma is generally poor, with median survival ranging from 8 to 14 months, and treatments are generally ineffective, especially in the case of sarcomatoid mesothelioma (7, 8). Thus, new diagnostic and therapeutic strategies are needed for mesothelioma, particularly the sarcomatoid type.

One promising area of antineoplastic drug development is to explore tumor susceptibility to targeted therapy (9–12). In principle, a variety of antitumor agents can be attached to tumor recognition molecules that target tumor-associated internalizing cell surface molecules to achieve intracellular delivery and targeted tumor killing (9, 11, 13). Currently, very few mesothelioma-associated cell surface markers that are expressed by all subtypes of mesothelioma are known (14). For example, mesothelin, a cell surface glycoprotein, has been shown to be a useful marker for epithelioid mesothelioma (15), but it is not expressed by the sarcomatous subtype of this disease (16). In addition, mesothelin is also expressed on normal mesothelial cells (16). Thus, the development of targeted therapies against mesothelioma will benefit from the identification of additional cell surface markers with more restricted expression on normal tissues and more specific associations with both epithelioid and sarcomatoid mesotheliomas.

Monoclonal antibodies (mAb) are able to recognize antigenic determinants of diverse chemical composition with high affinity and specificity and are, therefore, promising candidates for the development of targeted cancer therapies. Antibodies targeting tumor-associated epitopes could be used in applications such as induction of antibody-dependent cell cytotoxicity or inhibition of signaling pathways involved in tumor cell migration, growth, and survival. In addition, antibodies targeting internalizing tumor epitopes could be exploited to achieve specific intracellular delivery of therapeutic agents (9, 17, 18).

We have previously selected a naive phage antibody display library on mesothelioma cell lines derived from both epithelioid and sarcomatoid subtypes and identified a panel of internalizing mAbs that target cell surface antigens associated with both...
subtypes of mesothelioma (19). Most importantly, immunohistochemistry studies showed that these scFvs bind to mesothelioma cells in situ, thereby recognizing clinically represented tumor antigens. We have further exploited the internalizing function of these scFvs to deliver immunoliposomes encapsulating the small molecule drug topotecan specifically to mesothelioma cells and showed targeted killing of both epithelioid and sarcomatous mesothelioma cells in vitro (19). To facilitate further therapeutic development, we have begun to identify antigens recognized by this panel of phage antibodies. We have previously reported the construction of a large yeast surface-displayed human cDNA library, which was used to identify cellular proteins binding to posttranslational modifications (20) and small signaling molecules (21). In this report, we describe the identification of one of the target antigens, MCAM/CD146/MUC18, by screening the yeast surface human cDNA display library with a mesothelioma-targeting phage antibody. Mesothelioma tissue microarray studies showed that MCAM is overexpressed on >80% of both epithelioid and sarcomatous mesothelioma tissues, but not normal mesothelium. Finally, using single-photon emission computed tomography/computed tomography (SPECT/CT), we showed that the technetium (99mTc)-labeled anti-MCAM scFv was able to detect tumor cells in mesothelioma organ xenografts in vivo, suggesting that this scFv may be useful for the development of targeted immunotherapies against mesothelioma.

Materials and Methods

Materials. Reagents used for mammalian cell transfection are Lipofectamine 2000 and Opti-MEM (Invitrogen). Reagents used for scFv purification and characterization are nitrilotriacetic acid-nickel (Ni-NTA) agarose beads (Qiagen), EZ-Link Sulfo-NHS-LC-Biotin (Pierce), and streptavidin Qdot 705 conjugate (Invitrogen). Reagents used for fluorescence-activated cell sorting (FACS) and immunohistochemistry are streptavidin-phycocerythrin (SA-PE; Invitrogen/BioSource), streptavidin-Alexa 488 and 647 (SA-488 and SA-647; Invitrogen/Molecular Probes), affinity-purified anti-MCAM/CD146 antibody (Invitrogen), antihuman cytokeratin mAb AE1/AE3 (Dako), anti-CD34 mAb (Chemicon/Millipore), biotin-labeled rabbit anti-fd bacteriophage (Sigma-Aldrich), HRP-conjugated goat anti-mouse and HRP-conjugated goat anti-human (heavy and light chain) antibodies (Jackson ImmunoResearch), 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonate), diaminobenzedine tetrahydrochloride (DAB; Sigma-Aldrich), antigen unmasking solution and hematoxylin (Vector Laboratories), and optimal cutting temperature (OCT) compound (Sakura Finetec USA).

Human tissues. The protocol for tissue acquisitions was approved by the institutional review board and in accordance with an assurance filed with and approved by the Department of Health and Human Services. Surgically removed mesothelioma tissues were either embedded in paraffin to create tissue microarrays (22, 23) or maintained as organ cultures (tumor fragment spheroids), as previously described (24).

Production of scFvs. To produce soluble scFvs, genes encoding scFvs were cloned into an expression vector imparting a c-myc and a hexahistidine tag at the COOH terminus (25, 26). After isopropyl-L-thio-B-D-galactopyranoside induction, bacterial cells were harvested by centrifugation, resuspended in 200 mg/mL sucrose, 1 mmol/L EDTA, 30 mmol/L Tris-HCl (pH 8.0), on ice for 30 min, and centrifuged again to collect the supernatant. The pellet was resuspended in 5 mmol/L MgSO4 on ice for 30 min and centrifuged to collect the supernatant. Both supernatants were pooled and loaded on a Ni+-NTA column preequilibrated with 15 mmol/L imidazole/PBS and washed with 20 mmol/L imidazole/PBS (26, 27). Bound scFvs were eluted with 250 mmol/L imidazole/PBS, dialyzed against PBS, and analyzed by spectrophotometry (BioMini).

Tissue microarray study. Mesothelioma tissue microarrays were treated with xylene to remove paraffin, rehydrated in 100%, 95%, and 70% ethanol.
Yeast surface CDNA display screen identifies MCAM as target antigen of M1 phage antibody. A, enrichment of yeast clones displaying protein fragments with affinity for the M1 phage antibody through several rounds of FACS. PE and Alexa-647 labeled detection agents were alternated between rounds to reduce the chance of selecting binders to detection agents. The FITC channel is included to indicate autofluorescence. The P3 gate indicates the population selected in each round. B, M1 phage antibody binding to yeast displaying a fragment of the MCAM extracellular domain. Control, yeast transfected with vector pYD1. C, diagram of the M1 phage-binding MCAM protein fragment. Black bar indicates the region in the MCAM protein corresponding to the recovered cDNA. SP, signal peptide; Igcam, immunoglobulin superfamily cell adhesion molecule domain; TM, transmembrane domain.

Antigen identification by screening a yeast surface-displayed human cDNA library. The yeast surface human cDNA display library (20, 21) was grown in SR-CAA (2% raffinose, 0.67% yeast nitrogen base, and 0.5% casamino acids) at 30°C. A colonization step was performed in the presence of 0.5 in SRG-CAA (SR-CAA + 2% galactose) and grown at 30°C for 16 to 36 h. Induction was monitored by an anti-Xpress mAb (Invitrogen). After confirmation, M1 phage antibody and control helper phage were incubated with transfected cells, and binding was detected by biotin-labeled anti-fd bacteriophage followed by SA-PE.

Ectopic expression of MCAM in mammalian cells. Plasmids containing full-length human MCAM cDNA (pCMV-MCAM, OriGene) or a control human cDNA, GLG1 (pCMV-GLG1), under control of the CMV promoter were mixed with Lipofectamine 2000 and Opti-MEM, according to the manufacturer’s instructions, and incubated with BPH-1 cells growing at 80% confluency in 24-well plates. All experiments were done in triplicate. Expression of MCAM was checked at day 3 using an anti-MCAM antibody (Invitrogen). After confirmation, M1 phage antibody and control helper phage were incubated with transfected cells, and binding was detected by biotin-labeled anti-fd bacteriophage followed by SA-PE.

Labeling of scFv with near IR emitting quantum dots. A near IR fluorescent nanometer crystal with a polymer shell directly coupled to streptavidin (Qdot streptavidin 705 conjugate, Invitrogen) was conjugated to the anti-MCAM scFv or control scFv in two steps. First, the scFv was biotin-labeled with Sulfo-NHS-LC-Biotin for 30 min at room temperature according to manufacturer’s instructions and purified by elution with PBS (pH 7.2) through a gel filtration PD-10 column containing Superdex-G25 (GE Healthcare). Next, the purified biotin-labeled scFvs were incubated with the streptavidin-Qdot 705 for 30 min at room temperature to form the final conjugates, which were purified by eluting with PBS through a PD-10 column containing Superdex-200. By measuring the molar extinction coefficient at 280 and 705 nm, the final concentration of scFvs and Qdot 705 was estimated at 0.8 and 0.5 μmol/L, respectively.
Incubation of scFvs with human tumor fragment spheroids ex vivo.
Tumor fragment spheroids (24) were incubated with Qdot 705–conjugated anti-MCAM or control scFvs at 50 nmol/L for 4 h at 37°C. Tumor fragments from three tumors were used (two epithelial, one mixed). Ten spheroids were incubated with each antibody. After 4 h, the spheroids were washed with media, allowed to sediment, embedded in OCT, and frozen in liquid nitrogen for later sectioning. Cryosectioned specimens (10-μm thickness) were viewed by confocal microscopy in the near-IR spectrum using a Zeiss LSM510 microscope (Carl Zeiss Microimaging). In separate staining, the tumor fragments were stained with antihuman cytokeratin AE1/AE3 antibodies to confirm the presence of mesothelioma cells.

Preparation of [99mTc(CO)3(OH2)3]+. The IsoLink kit (Tyco/Mallinckrodt) was used to prepare the [99mTc(CO)3(OH2)3]+ moiety. A 10-ml penicillin vial containing potassium boronacarboneate (8.5 mg, 63 μmol), sodium tetraborate-10H2O (2.9 mg, 8.0 μmol), Na-tartrate (15.0 mg, 53 μmol), and Na2CO3 (4.0 mg, 38 μmol) was fitted with a rubber septum, and the vial flushed with N2(g) for 15 min. 99mTcO4− eluted from the 99Mo/99mTc generator (GE Healthcare; 370 MBq, 10–20 mCi) in 1.0 μL of saline was added by a syringe, and the solution was heated to 100°C for 30 min. After cooling on ice, the alkaline solution was neutralized to final pH 6.0 to 6.5 by the addition of 180 to 200 μL of 1 mol/L HCl. Quality control was performed by reverse-phase high-performance liquid chromatography.

Radiolabeling of scFv. An aliquot (20–30 μL) of scFv solution at 5 mg/mL was mixed with 100 to 500 μL of [99mTc(CO)3(OH2)3]+ solution, and the mixture was heated at 37°C for 60 min. The reaction mixture was cooled down to room temperature, and the product was isolated using a PD-10 column containing Superdex-G25 with PBS (pH 7.2) as eluant (28). Both the anti-MCAM scFv (M1) and the control scFv (N3M2), which was randomly picked from the unselected naive phage antibody library and purified in the same way, were labeled and randomly picked from the unselected naive phage antibody library and tested for lack of binding to tumor cell lines by FACS, were labeled and purified in the same way. The specific activities of these labeled scFvs were similar (within SDs).

In vivo SPECT/CT and biodistribution studies. Animal studies were approved by the institutional review board and adhered to the USPHS policy on humane care and use of laboratory animals. Tumor fragment spheroids (1 × 2 × 2 mm3 size) generated from human mesothelioma tissues were injected into the peritoneal space of the nude mice (Ncr nu/nu, Taconic) – 4 wk before the imaging experiment (24). Ten nude tumor-bearing mice were each injected via the tail vein with 18.5 MBq of the 99mTc anti-MCAM scFv (50 μg) in 100 μL PBS. As a control, 10 nude tumor-bearing mice were each injected with 18.5 MBq of the 99mTc-labeled control scFv. The mice were imaged with a combined modality SPECT/CT (X-SPECT, Gamma Medica) at 2, 4, 6, and 8 h and then sacrificed and dissected for immunohistochemistry and biodistribution studies. For immunohistochemistry, a fraction of the excised tumor was embedded in paraffin and analyzed by immunohistochemistry using anti-AE1/AE3 mAb and an anti-MCAM antibody (Invitrogen) to confirm the presence of tumors and HRP-conjugated goat anti-human antibodies to confirm the presence of human scFvs. For biodistribution studies, tumors, blood, and major organs were collected and weighed wet. The radioactivity in these samples was measured using a Gamma counter, calibrated against a known quantity of the injected dose, and presented as percentage of injected dose per gram (%ID/g).

Statistics. The two-tailed Student’s t test was used to analyze a pair of variables, and a P value of <0.05 was considered statistically significant. Where appropriate, the data are presented as mean ± SD.

Results
The mesothelioma-targeting M1 phage antibody binds MCAM. Using our recently developed expression cloning strategy based on yeast surface human proteome display (20, 21), we have begun to systematically identify mesothelioma cell surface antigens bound by our panel of internalizing phage antibodies. We initially focused our identification efforts on the scFv M1, which binds to a broad panel of tumor cell lines and may thus recognize a commonly expressed tumor cell surface antigen. We have previously constructed an inducible library of human protein fragments displayed on the yeast surface as COOH terminal fusions to the yeast α-αgglutinin subunit Aga2p and showed utility of this library in mapping protein-ligand interactions (20, 21). We used a similar strategy (Fig. 1) to identify the M1-targeted mesothelioma antigen using the M1 phage antibody as the "bait" to select binding clones from the yeast surface cDNA display library by FACS (20, 21).

The induced yeast surface-displayed human cDNA library was incubated with biotin-labeled phage antibody, and binding clones were enriched through three rounds of FACS. Very few binding clones (<0.5%) were present in the initial library population (Fig. 2A, Rd1). After two rounds of selection, >15% of the yeast population bound the phage antibody (Fig. 2A, Rd3). Individual yeast clones from the third round output population were screened by FACS. Plasmids from M1 phage-binding clones were recovered, retransformed into yeast to verify the results of the primary screen, and sequenced to determine the identity of their cDNA inserts. One
unique cDNA insert was identified from four clones that bind to the M1 phage antibody (Fig. 2B). This cDNA sequence matched perfectly with a portion of the extracellular domain of MCAM (Fig. 2C), also known as MUC18 or CD146.

To confirm that MCAM is indeed the antigen bound by the M1 phage antibody, we transiently transfected mammalian cells (BPH-1) that do not express MCAM with a mammalian expression vector containing full-length MCAM cDNA (pCMV-MCAM). After confirming surface expression of MCAM by FACS using an anti-MCAM antibody (Fig. 3A), we stained transfected cells with the M1 phage antibody and showed that the M1 phage binds MCAM expressed on the surface of mammalian cells (Fig. 3B), confirming that MCAM is the tumor antigen recognized by our M1 phage antibody.

MCAM is expressed in mesothelioma tissues. To determine how widely MCAM is expressed by mesothelioma, we performed immunohistochemistry studies on mesothelioma tissue arrays. MCAM was found to be expressed in >80% of mesothelioma specimens of all subtypes [epithelioid (28 of 31), sarcomatoid (8 of 10), and mixed type (14 of 14); examples are shown in Fig. 4]. MCAM is not expressed on normal mesothelium (Fig. 4). In addition to tumor cells, MCAM was found to be expressed strongly on tumor-associated blood vessels (Fig. 4), consistent with previous reports that MCAM is a marker for angiogenesis (29, 30). These experiments show that MCAM is widely expressed by all subtypes of mesothelioma and tumor-associated blood vessels and may, thus, be an attractive therapeutic target.

The anti-MCAM scFv targets human mesothelioma cells in ex vivo cultured tumor fragments. To determine whether the anti-MCAM scFv would target primary human mesothelioma cells, we labeled the anti-MCAM scFv with a near IR quantum dot (Qdot 705) and incubated the labeled scFv with tumor fragment spheroids grown from mesothelioma obtained from surgical resection (24). After a 4-h incubation at 37°C with labeled anti-MCAM scFv, tumor spheroids were frozen and cryosectioned for viewing by confocal microscopy. In tumor fragments from five different mesotheliomas, the anti-MCAM scFv was found to stain tumor cells in all cases (an example is shown in Fig. 5A). The cells bound by the anti-MCAM scFv were confirmed to be mesothelioma cells by cytokeratin stain (ref. 24; Fig. 5A). The sections incubated with a Qdot 705–labeled control scFv showed no binding. These data show that the anti-MCAM scFv can specifically target primary mesothelioma cells ex vivo in mesothelioma organ culture spheroids.

The anti-MCAM scFv targets xenografted mesothelioma tissues in vivo. To determine the efficiency of the anti-MCAM scFv in tumor targeting in vivo, we performed molecular imaging studies with technetium (99mTc)-labeled scFv and a combined modality SPECT/CT, which allows simultaneous tomographic imaging of γ-emitting radiopharmaceuticals and anatomic imaging with CT. To increase clinical relevance, we used a novel xenograft model that uses peritoneally implanted fragments of human mesothelioma (24). Mice carrying peritoneally implanted human mesothelioma tissues were injected with either 99mTc-labeled anti-MCAM M1 scFv or a 99mTc-labeled control scFv and imaged with SPECT/CT. As shown in Fig. 5B, peritoneally grafted human mesothelioma tissues were recognized by 99mTc-labeled anti-MCAM scFv but not the control scFv, demonstrating the targeting specificity in vivo. The other organs that showed the greatest contrast were the kidneys and the bladder, consistent with the known route of scFv excretion from the body. After imaging, the tumor fragment spheroid tissues were removed from the mice, sectioned, and stained for human cytokeratin (a mesothelioma marker) to identify the tumor cells and for MCAM to confirm tumor expression of this molecule (Fig. 5C). We further used antihuman (heavy and light chains) antibodies to confirm scFvs in the tissue sections (Fig. 5C).
Next, we performed biodistribution studies using the $^{99m}$Tc-labeled anti-MCAM and control scFvs. Antibody accumulation in tumor, blood, and major organs was determined at 8 h after injection (Fig. 6A). The anti-MCAM scFv showed higher tumor accumulation in mice carrying mesothelioma tissue xenografts than the control scFv (Fig. 6A), demonstrating targeting specificity of the anti-MCAM scFv. The relative uptake ratios (M1/control) were higher for tumor xenografts compared with other organ sites studied (Fig. 6B).

**Discussion**

We have previously selected a panel of human scFvs from a phage antibody library that bind to clinically represented, internalizing epitopes on the mesothelioma cell surface (19). We have further shown that these scFvs can mediate tumor-specific intracellular delivery of small molecule drugs, which selectively kill mesothelioma cells in vitro (19). In this study, we sought to identify the target antigen bound by one of these antibodies, the M1 scFv. We focused our initial identification efforts on the M1 scFv because it has shown payload delivery function and binds to several tumor cell lines in addition to mesothelioma cell lines, suggesting that it may be broadly useful as a tumor-targeting agent (19).

Identification of MCAM as a Mesothelioma Antigen

The discovery of MCAM expression in mesothelioma tissues is significant for therapeutic development against this disease for several reasons. First, our study showed that MCAM is expressed by...
all subtypes of mesothelioma. In contrast, mesothelin, a currently used marker for mesothelioma, recognizes the epithelioid but not the sarcomatous subtype of mesothelioma (16), a particularly recalcitrant form of this disease. Second, consistent with previous reports of MCAM expression on blood vessels (29, 30), our study using mesothelioma tissue microarrays showed that MCAM is expressed on both mesothelioma cells and tumor-associated blood vessels, making MCAM a potentially attractive target for a combined antitumor and antiangiogenesis therapy (38). Finally, our results show that overlapping sets of cell surface antigens exist between tumors of diverse tissue origins. Whereas the etiology of mesothelioma may be unique, it nevertheless shares characteristics with other commonly occurring tumors, such as melanoma. Treatment of mesothelioma may, thus, benefit from ongoing therapeutic development for other oncological indications.

Using human tumor fragments cultured ex vivo, we showed that the anti-MCAM scFv penetrates the tumor fragments and homes specifically to primary mesothelioma cells. To be useful for targeted therapy, antibodies or antibody fragments must be able to accumulate in tumor tissues in vivo after systemic administration. The in vivo biodistribution of the anti-MCAM M1 scFv was evaluated in a novel mesothelioma organotypic xenograft model using SPECT/CT. SPECT/CT combines functional imaging (SPECT) and structural imaging (CT) to achieve accurate and sensitive tumor detection in vivo. We found that the anti-MCAM M1 scFv, but not the control scFv, preferentially accumulated in mesothelioma xenografts compared with surrounding soft tissues, demonstrating its potential in noninvasive imaging and targeted immunotherapy. This result is most impressive because the organotypic xenograft model is more clinically relevant compared with models based on cell lines (24).

We have selected scFvs on live mesothelioma cells to identify those that target novel internalizing epitopes. These scFv-targeted epitopes are in their native conformation as opposed to MHC-presented ones. As such, these scFvs are well suited for targeting live tumor cells ex vivo and in vivo, as we have shown in this study, but may have limitations in detecting denatured epitopes, such as those in paraffin-embedded tissues. For example, the M1 scFv binds to live mesothelioma cells and mesothelioma cells in situ in frozen tissues, as we have shown previously, (19) but does not stain paraffin-embedded tissues. As such, we have used the commercial anti-MCAM antibody to stain the paraffin-embedded mesothelioma tissue arrays.

We used a novel, FACS-based expression cloning strategy based on yeast surface cDNA display to identify the target antigen. The yeast display technology was originally developed by Wittrup and colleagues to study eukaryotic protein functions (39–41). We have previously adapted this technology for human proteome display and constructed a large yeast surface display human cDNA fragment library (20, 21). We screened the library by FACs to identify cellular proteins binding to posttranslational modifications (20) and small molecules (21). A major advantage of this cloning system is that the bait can be of diverse chemical and molecular composition, as long as it can be fluorescently detected (20, 21). In this study, we used phage particles displaying the M1 scFv as the bait, greatly simplifying the identification process. Because 50,000 to 70,000 cells can be sorted per second, the FACS-based method allows the full diversity of large libraries to be practically screened.
The combination of phage antibody library selection on the surface of living tumor cells and rapid target antigen identification by screening the yeast surface-displayed human proteome could be a powerful method for mapping the tumor cell surface epitope space.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
Received 4/11/2008; revised 10/23/2008; accepted 11/14/2008; published OnlineFirst 02/03/2009.

Grant support: NIH grants R01 CA118919 (B. Liu) and CA95671 (V.C. Broadus) and Mesothelioma Applied Research Foundation (B. Liu and V.C. Broadus).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Stephen L. Nishimura for help with histopathology study and Dr. Shannon Wilson for help with tumor fragment spheroid experiments.

References
Identification of MCAM/CD146 as the Target Antigen of a Human Monoclonal Antibody that Recognizes Both Epithelioid and Sarcomatoid Types of Mesothelioma

Scott Bidlingmaier, Jiang He, Yong Wang, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-08-1363

Cited articles
This article cites 41 articles, 13 of which you can access for free at:
http://cancerres.aacrjournals.org/content/69/4/1570.full#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/69/4/1570.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.